tetano
Editor, Senior Moderator
Eur J Med Res
. 2024 Jul 5;29(1):356.
doi: 10.1186/s40001-024-01956-8. Alopecia areata following COVID-19 vaccine: a systematic review
Yunxia Zhu[SUP] 1 [/SUP], Xiaoliang Ouyang[SUP] 2 [/SUP], Deng Zhang[SUP] 1 [/SUP], Xiuping Wang[SUP] 1 [/SUP], Liang Wu[SUP] 1 [/SUP], Simin Yu[SUP] 1 [/SUP], Yanping Tan[SUP] 3 [/SUP], Wei Li[SUP] 4 [/SUP], Chunming Li[SUP] 5 [/SUP]
Affiliations
Background: To date, multiple cases of adverse reactions to COVID-19 vaccines have been reported worldwide. Alopecia areata (AA) is an uncommon type of adverse reaction reported in some articles and has a significant social and psychological impact on patients. Our study aimed to review the AA and COVID-19 vaccine literature.
Methods: This systematic review was conducted by searching for articles on AA following COVID-19 vaccines in international databases such as Embase, MEDLINE, PubMed, Web of Knowledge, and Ovid from December 2019 to December 30, 2023. We included studies that provided data for AA patients following COVID-19 vaccination with at least one dose. Data on sex, age, country/region of origin, vaccine type, days between vaccination and symptom presentation, manifestations of AA, trichoscopy and histopathological findings, treatment, and outcomes were included.
Results: In total, 579 explored studies were identified and assessed, and 25 articles with a total of 51 patients were included in the review. Twenty-seven (52.9%) patients developed new-onset AA following receiving the COVID-19 vaccine, and AA recurrence or exacerbation occurred after receiving the COVID-19 vaccine in 24 (47.1%) patients with preexisting disease. Five vaccines were reported to cause AA in all cases. The Pfizer vaccine (45.1%) was the most frequently reported, followed by the ChAdOx1 nCoV-19 vaccine (27.5%), Moderna mRNA-1273 (19.6%), Sinopharm (3.9%) and SinoVac (3.9%). AA occurred most frequently within one month after the 1st dose, and then, the incidence decreased gradually with time. Topical or systemic corticosteroids were used in 38 patients. Eleven patients were treated with a Janus Kinase inhibitor (jakinib) inhibitor, eight with tofacitinib, and three with an unspecified jakinib. However, 3 of the 11 patients experienced exacerbations after treatment.
Conclusion: AA after COVID-19 vaccination is rare, and physicians should be aware of this phenomenon to improve early diagnosis and appropriate treatment.
Keywords: Adverse reactions; Alopecia areata; COVID-19 vaccines; Immunity; SARS-CoV-2.
. 2024 Jul 5;29(1):356.
doi: 10.1186/s40001-024-01956-8. Alopecia areata following COVID-19 vaccine: a systematic review
Yunxia Zhu[SUP] 1 [/SUP], Xiaoliang Ouyang[SUP] 2 [/SUP], Deng Zhang[SUP] 1 [/SUP], Xiuping Wang[SUP] 1 [/SUP], Liang Wu[SUP] 1 [/SUP], Simin Yu[SUP] 1 [/SUP], Yanping Tan[SUP] 3 [/SUP], Wei Li[SUP] 4 [/SUP], Chunming Li[SUP] 5 [/SUP]
Affiliations
- PMID: 38970130
- PMCID: PMC11225413
- DOI: 10.1186/s40001-024-01956-8
Background: To date, multiple cases of adverse reactions to COVID-19 vaccines have been reported worldwide. Alopecia areata (AA) is an uncommon type of adverse reaction reported in some articles and has a significant social and psychological impact on patients. Our study aimed to review the AA and COVID-19 vaccine literature.
Methods: This systematic review was conducted by searching for articles on AA following COVID-19 vaccines in international databases such as Embase, MEDLINE, PubMed, Web of Knowledge, and Ovid from December 2019 to December 30, 2023. We included studies that provided data for AA patients following COVID-19 vaccination with at least one dose. Data on sex, age, country/region of origin, vaccine type, days between vaccination and symptom presentation, manifestations of AA, trichoscopy and histopathological findings, treatment, and outcomes were included.
Results: In total, 579 explored studies were identified and assessed, and 25 articles with a total of 51 patients were included in the review. Twenty-seven (52.9%) patients developed new-onset AA following receiving the COVID-19 vaccine, and AA recurrence or exacerbation occurred after receiving the COVID-19 vaccine in 24 (47.1%) patients with preexisting disease. Five vaccines were reported to cause AA in all cases. The Pfizer vaccine (45.1%) was the most frequently reported, followed by the ChAdOx1 nCoV-19 vaccine (27.5%), Moderna mRNA-1273 (19.6%), Sinopharm (3.9%) and SinoVac (3.9%). AA occurred most frequently within one month after the 1st dose, and then, the incidence decreased gradually with time. Topical or systemic corticosteroids were used in 38 patients. Eleven patients were treated with a Janus Kinase inhibitor (jakinib) inhibitor, eight with tofacitinib, and three with an unspecified jakinib. However, 3 of the 11 patients experienced exacerbations after treatment.
Conclusion: AA after COVID-19 vaccination is rare, and physicians should be aware of this phenomenon to improve early diagnosis and appropriate treatment.
Keywords: Adverse reactions; Alopecia areata; COVID-19 vaccines; Immunity; SARS-CoV-2.